Skip to main content

Table 1 The baseline characteristics and clinical outcomes in the PCOS group and the control group before PSM

From: Pregnancy outcomes in patients with polycystic ovary syndrome who conceived after single thawed blastocyst transfer: a propensity score-matched study

variables control group PCOS group P-value
n 2325 336  
Female age (year) 32, 6a 30, 5b  < 0.001
BMI (kg/m2) 20.8, 3.5 21.6, 3.8  < 0.001
     < 24 84.6%a 75.6%b  
      ≥ 24 15.4%a 24.4%b  
Basal FSH (IU/L) 5.28, 1.57a 4.83, 1.58b  < 0.001
Basal LH (IU/L) 3.16, 1.78a 5.75, 5.39b  < 0.001
Basal TT (ng/mL) 0.29, 0.13a 0.42, 0.22b  < 0.001
Endometrial preparation     < 0.001
     HRT cycles 43.1% (1001/2325)a 75.6% (254/336)b  
     NCs 44.0% (1024/2325)a 8.3% (28/336)b  
     LE cycles 6.1% (142/2325)a 12.2% (41/336)b  
     GnRH-a cycles 6.8% (158/2325)a 3.9% (13/336)b  
Blastocyst expansion stage    0.386
     expansion stage < 4 6.9% 5.7%  
     expansion stage ≥ 4 93.1% 94.3%  
Inner cell mass grade    0.276
     A 38.3% 42.5%  
     B 58.1% 54.8%  
     C 3.6% 2.7%  
Trophectoderm grade    0.021
     A 22.4%a 25.9%a  
     B 68.3%a 69.0%a  
     C 9.3%a 5.1%b  
     Miscarriage rate 16.4% 17.3% 0.686
     Pregnancy complications rate 24.0% 25.6% 0.512
     Preterm birth rate 8.2% 10.7% 0.118
     live birth rate 81.1% 79.5% 0.471
  1. Non-normally distributed continuous data is presented with median and interquartile range. Categorical data are presented with percentages. BMI Body mass index, FSH Follicle-stimulating hormone, LH Luteinizing hormone, TT Total testosterone, HRT Hormone replacement treatment, NCs Natural cycles, LE Letrozole, GnRH-a GnRH agonist. Different letters represent statistically significant differences between the two groups (P-value < 0.05)